Treatment and prospect of mild cognitive impairment

Chinese Journal of Clinical Rehabilitation

Volumn 8, Issue 16, 2004, Pages 3111-3113

  Ye, Ni ^a   Peng, Hai ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); APOLIPOPROTEIN E; CELECOXIB; CYCLOOXYGENASE 2; DONEPEZIL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GINKGO BILOBA EXTRACT; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIVASTIGMINE; TACRINE; VELNACRINE;

AGE; ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE SEVERITY; GINKGO BILOBA; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 3543133554     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Palmer K, Fratiglioni L, Winblad B. What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand 2003; 7 (Suppl 179): 14-20
2. Chinese source. 2003, 7(3): 496-7
3. Borroni B, Colciaghi F, Pastorrino L, et al. Amyloid precursor protein in platelets of patients with Alzheimer's disease. Arch Neurol 2001; 58: 442-6
4. Sramek JJ, Veriff AE, Culter NR. The status of ongoing trials for mild cognitive impairment. Expert Opin Invest Drugs, 2001; 10: 741-52
5. Dekosky ST, Ikonsomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex olderly sunjects with mild cognitive impairment. Amr Neurol 2002; 51: 145-55
6. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, et al. Neuroprotection by memantine against neurodegeneration incluced by β-amyloid (1-40). Brain Res 2002; 958: 210-21
7. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med 1997; 36: 1216-22
8. Le Bars PL, Velasco FM, Fercuson JM, et al. Influence of the severity of cognitive impairment on the effect of the Ginko biloba extract Egb 761 in Alzheimer's disease. Neuropsychobiology 2002; 45: 19-26
9. In't Veld BA, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer's disease, the Rotterdam study. Neurobiol Aging 1998; 19: 607-11
10. Landi F, Cesari M, Onder G, et al. Non-steroidal anti-inflammatory drug(NSAID) use at Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry 2003; 11: 179-85
11. Barbara K, Martins PD, Curtis L, et al. Double placebo designs in a prevention trial for Alzheimer's disease. Controlled Clin Trials 2002; 23: 93-9
12. Tong MX, Jacobs D, Stem Y, et al. Effect of estrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-32
13. Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and therapy of Alzheimer's disease. Arch Neurol 2001; 58 (3): 435-40
14. Seshadri S, Zornberg GL, Derby LE, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease. Arch Neurol 2001;58: 415-40
15. Hogervorst E, Smith AD. The interaction of serum folate and estradiol level for Alzheimer's disease. Neuro Endocrinol Lett 2002; 23 (2): 155-60
16. Raber J, Bongers G, LeFevour A, et al. Androgens protect against apolipoprotein E4-induced cognitive deficits. J Neurosci 2002; 22 (12): 5204-9
17. Ramsden M, Nyborg AC, Murphy MP, et al. Androgens modulate beta-amyloid levels in male rats brain. J Neurochem 2003; 7 (4): 1052-5
18. Chinese source. 2003, 7(19): 2702-3
19. Kirschling CM, Kolsch H, Frahnert C, et al. Polymorphism in the BACE gene influences the risk for Alzheimer's disease. Neuroreport 2003; 14 (9): 1243-6
20. Chinese source. 2003, 7(31): 4262-3
21. Tamagno E, Guglielmotto M, Bardini P, et al. Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. Neurobiol Dis 2003; 14 (2): 291-301
22. Liu SJ, Zhang AH, Li HL, et al. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 2003; 87 (6): 1333-44
23. Takashima A, Murayama M, Yasutake K. Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 2001; 306 (1-2): 37-40
24. Arendt T, Holzer M, Gartner U, et al. Aberrancies in signal transduction and cell cycle related events in Alzheimer's disease. J Neurol Transm 1998; 54: 147-58
25. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-α attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7
26. Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-α homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol 2001; 159: 439-47
27. Marr RA, Rockenstein E, Mukherjee A, et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci 2003; 23 (6): 1992-6